1
|
Deh K, Zhang G, Park AH, Cunningham CH, Bragagnolo ND, Lyashchenko S, Ahmmed S, Leftin A, Coffee E, Hricak H, Miloushev V, Mayerhoefer M, Keshari KR. First in-human evaluation of [1- 13C]pyruvate in D 2O for hyperpolarized MRI of the brain: A safety and feasibility study. Magn Reson Med 2024; 91:2559-2567. [PMID: 38205934 PMCID: PMC11009889 DOI: 10.1002/mrm.30002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 12/15/2023] [Accepted: 12/20/2023] [Indexed: 01/12/2024]
Abstract
PURPOSE To investigate the safety and value of hyperpolarized (HP) MRI of [1-13C]pyruvate in healthy volunteers using deuterium oxide (D2O) as a solvent. METHODS Healthy volunteers (n = 5), were injected with HP [1-13C]pyruvate dissolved in D2O and imaged with a metabolite-specific 3D dual-echo dynamic EPI sequence at 3T at one site (Site 1). Volunteers were monitored following the procedure to assess safety. Image characteristics, including SNR, were compared to data acquired in a separate cohort using water as a solvent (n = 5) at another site (Site 2). The apparent spin-lattice relaxation time (T1) of [1-13C]pyruvate was determined both in vitro and in vivo from a mono-exponential fit to the image intensity at each time point of our dynamic data. RESULTS All volunteers completed the study safely and reported no adverse effects. The use of D2O increased the T1 of [1-13C]pyruvate from 66.5 ± 1.6 s to 92.1 ± 5.1 s in vitro, which resulted in an increase in signal by a factor of 1.46 ± 0.03 at the time of injection (90 s after dissolution). The use of D2O also increased the apparent relaxation time of [1-13C]pyruvate by a factor of 1.4 ± 0.2 in vivo. After adjusting for inter-site SNR differences, the use of D2O was shown to increase image SNR by a factor of 2.6 ± 0.2 in humans. CONCLUSIONS HP [1-13C]pyruvate in D2O is safe for human imaging and provides an increase in T1 and SNR that may improve image quality.
Collapse
Affiliation(s)
- Kofi Deh
- Radiology, Memorial Sloan Kettering Cancer Center
| | | | - Angela Hijin Park
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | - Charles H. Cunningham
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario
- Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario
| | | | - Serge Lyashchenko
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | - Shake Ahmmed
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | | | | | - Hedvig Hricak
- Radiology, Memorial Sloan Kettering Cancer Center
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
| | | | | | - Kayvan R. Keshari
- Radiology, Memorial Sloan Kettering Cancer Center
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
| |
Collapse
|
2
|
Zhang G, Deh K, Park H, Cunningham CH, Bragagnolo ND, Lyashchenko S, Ahmmed S, Leftin A, Coffee E, Kelsen D, Hricak H, Miloushev V, Mayerhoefer M, Keshari KR. Assessment of the Feasibility of Hyperpolarized [1- 13 C]pyruvate Whole-Abdomen MRI using D 2 O Solvation in Humans. J Magn Reson Imaging 2024. [PMID: 38440941 DOI: 10.1002/jmri.29322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 02/14/2024] [Accepted: 02/14/2024] [Indexed: 03/06/2024] Open
Affiliation(s)
- Guannan Zhang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Kofi Deh
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Hijin Park
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Charles H Cunningham
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Sunnybrook Research Institute, Toronto, Ontario, Canada
| | | | - Serge Lyashchenko
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Shake Ahmmed
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | | | - Elizabeth Coffee
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - David Kelsen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Hedvig Hricak
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Vesselin Miloushev
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Marius Mayerhoefer
- Department of Radiology, NYU Grossman School of Medicine, New York City, New York, USA
| | - Kayvan R Keshari
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| |
Collapse
|
3
|
Di Gialleonardo V, Aldeborgh HN, Miloushev V, Folkers KM, Granlund K, Tap WD, Lewis JS, Weber WA, Keshari KR. Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. Cancer Res 2017; 77:3113-3120. [PMID: 28386017 DOI: 10.1158/0008-5472.can-16-3310] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 11/30/2016] [Accepted: 03/16/2017] [Indexed: 01/07/2023]
Abstract
Biomarkers predicting rapalog responses in sarcomas where PI3K and mTOR are often hyperactivated could improve the suitable recruitment of responsive patients to clinical trials. PI3K/mTOR pathway activation drives energy production by regulating anaerobic glycolysis in cancer cells, suggesting a route toward a monitoring strategy. In this study, we took a multimodality approach to evaluate the phenotypic effects and metabolic changes that occur with inhibition of the PI3K/mTOR pathway. Its central role in regulating glycolysis in human sarcomas was evaluated by short- and long-term rapamycin treatment in sarcoma cell lines. We observed an overall decrease in lactate production in vitro, followed by cell growth inhibition. In vivo, we observed a similar quantitative reduction in lactate production as monitored by hyperpolarized MRI, also followed by tumor size changes. This noninvasive imaging method could distinguish reduced cell proliferation from induction of cell death. Our results illustrate the use of hyperpolarized MRI as a sensitive technique to monitor drug-induced perturbation of the PI3K/mTOR pathway in sarcomas. Cancer Res; 77(11); 3113-20. ©2017 AACR.
Collapse
Affiliation(s)
- Valentina Di Gialleonardo
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Hannah N Aldeborgh
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Vesselin Miloushev
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Kelly M Folkers
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Kristin Granlund
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - William D Tap
- Medicine Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Jason S Lewis
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Medicine Memorial Sloan Kettering Cancer Center, New York, New York
| | - Wolfgang A Weber
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Weill Cornell Medical College, New York, New York
| | - Kayvan R Keshari
- Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. .,Weill Cornell Medical College, New York, New York
| |
Collapse
|
4
|
Tee SS, DiGialleonardo V, Eskandari R, Jeong S, Granlund KL, Miloushev V, Poot AJ, Truong S, Alvarez JA, Aldeborgh HN, Keshari KR. Sampling Hyperpolarized Molecules Utilizing a 1 Tesla Permanent Magnetic Field. Sci Rep 2016; 6:32846. [PMID: 27597137 PMCID: PMC5011774 DOI: 10.1038/srep32846] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Accepted: 08/09/2016] [Indexed: 02/06/2023] Open
Abstract
Hyperpolarized magnetic resonance spectroscopy (HP MRS) using dynamic nuclear polarization (DNP) is a technique that has greatly enhanced the sensitivity of detecting 13C nuclei. However, the HP MRS polarization decays in the liquid state according to the spin-lattice relaxation time (T1) of the nucleus. Sampling of the signal also destroys polarization, resulting in a limited temporal ability to observe biologically interesting reactions. In this study, we demonstrate that sampling hyperpolarized signals using a permanent magnet at 1 Tesla (1T) is a simple and cost-effective method to increase T1s without sacrificing signal-to-noise. Biologically-relevant information may be obtained with a permanent magnet using enzyme solutions and in whole cells. Of significance, our findings indicate that changes in pyruvate metabolism can also be quantified in a xenograft model at this field strength.
Collapse
Affiliation(s)
- Sui Seng Tee
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Valentina DiGialleonardo
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Roozbeh Eskandari
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Sangmoo Jeong
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Kristin L Granlund
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Vesselin Miloushev
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Alex J Poot
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | | | - Hannah N Aldeborgh
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Kayvan R Keshari
- Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.,Weill Cornell Medical College, NY 10065, USA
| |
Collapse
|